• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Current status of clinical outcome measures in inclusion body myositis: a systematised review
CONCLUSIONS: There are inconsistencies in using outcome measures in clinical studies in IBM. The core set measures developed by the IMACS group for other IIMs are not directly applicable to IBM. As a result, there is an unmet need for an IBM-specific core set of measures to facilitate the evaluation of new potential therapeutics for IBM.PMID:36762744 | DOI:10.55563/clinexprheumatol/ifacv3
Source: Clinical and Experimental Rheumatology - February 10, 2023 Category: Rheumatology Authors: Bhaskar Roy Matteo Lucchini James B Lilleker Namita A Goyal Elie Naddaf Brittany Adler Lindsay N Alfano Georgia A Malandraki Kendrea L Focht Garand David Mochel Umesh Badrising Pedro M Machado Ruben Pagkatipunan Leo Wang Melissa C Funaro Jens Schmidt Hani Source Type: research

Prevalence and clinical significance of electrocardiographic signs of atrial myopathy in rheumatoid arthritis: results from the EDRA study
CONCLUSIONS: Electrocardiographic markers of atrial myopathy are independently associated with RA. Further studies with larger sample size and longer follow-up are needed to determine whether the increased prevalence of atrial myopathy contributes to the increased risk of atrial fibrillation and stroke in this group.PMID:36622121 | DOI:10.55563/clinexprheumatol/d9l4lt
Source: Clinical and Experimental Rheumatology - January 9, 2023 Category: Rheumatology Authors: Giuseppe D Sanna Matteo Piga Anna Piga Olga Falco Enrico Ponti Alberto Cauli Alberto Floris Arduino A Mangoni Gavino Casu Giuseppe De Luca Gian Luca Erre EDRA Study Group Source Type: research

In-patient comorbidities in inclusion body myositis: a United States national in-patient sample-based study
CONCLUSIONS: IBM increases a patient's risk for dysphagia, falls, and infection as compared to other IIM patients. Further population-based studies are warranted to better elucidate the impact of these comorbidities in patients with IBM.PMID:36377563 | DOI:10.55563/clinexprheumatol/791fq8
Source: Clinical and Experimental Rheumatology - November 15, 2022 Category: Rheumatology Authors: Anthony K Ma Feng Dai Bhaskar Roy Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11